While the LIVE and FIGHT trials explored their effects on heart failure with reduced ejection fraction (HFrEF), the STEP-HFpEF trial demonstrated that GLP-1RAs improve HFpEF outcomes by reducing symptoms, physical limitations, and body weight [9]
Trials are investigating whether these drugs can reduce risks of cardiovascular disease, fatty liver, and even dementia
Czy BPC-157 ma skutki uboczne i czy jest bezpieczny
As a result, nutrients (including glucose) enter your bloodstream more slowly, reducing post-meal blood sugar spikes
I have been long LLY and NVO because of GLP-1 drugs since early 2022, but as evidence continues to amass in favour of their utility for a large population its worth considering - what other implications does this have
Those with low L-carnitine levels may benefit from taking an oral supplement